КОНТРОЛЬ ЛИПИДОВ У ПАЦИЕНТОВ ПОСЛЕ ПЕРЕНЕСЕННОГО ИНФАРКТА МИОКАРДА — ЭФФЕКТИВНЫЙ ИНСТРУМЕНТ УПРАВЛЕНИЯ СЕРДЕЧНО-СОСУДИСТЫМ РИСКОМ
https://doi.org/10.21518/2307-1109-2017-1-94-104
Аннотация
В обзорной статье освещены позиции современных клинических рекомендаций в отношении назначения высокоинтенсивной терапии статинами и нестатиновыми холестеринснижающими препаратами у пациентов очень высокого сердечно-сосудистого риска после перенесенного инфаркта миокарда, а также цели терапии. Обозначены подходы к контролю параметров липидограммы после назначения высокоинтенсивной терапии статинами и к назначению ингибиторов PCSK9 (алирокумаб) после развития острого коронарного события. Для составления обзорной статьи использованы доступные материалы из отечественных и зарубежных библиотечных баз данных (e-Library, Library’s MEDLINE/PubMed database).
Об авторах
О. Л. Барбараш
Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний, г. Кемерово; Кемеровский государственный медицинский университет Минздрава России
Россия
чл.-корр. РАН, д.м.н., профессор
Россия
чл.-корр. РАН, д.м.н., профессор
В. В. Кашталап
Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний; Кемеровский государственный медицинский университет Минздрава России
Россия
д.м.н.
Россия
д.м.н.
Список литературы
1. Garganeeva AA, Okrugin SA, Efimova EA, Borel KN. Register of acute myocardial infarction» as information population system of evaluation of epidemiological situation and medical care of patients with acute myocardial infarction. Serdce, 2013, 1(12): 37-41 (in Russian). Гарганеева А.А., Округин С.А., Ефимова Е.В., Борель К.Н. «Регистр острого инфаркта миокарда» как информационная популяционная система оценки эпидемиологической ситуации и медицинской помощи больным острым инфарктом миокарда. Сердце, 2013, 1(12): 37-41.
2. Ehrlich AD, Barbarash OL, Kashtalap VV, Gratsiansky NA on behalf of all participants of the RECORD-3 registry. Compliance with clinical practice guidelines for non ST-segment elevation acute coronary syndrome: association between outcomes and predictors of poor management (RECORD-3 Registry data). Complex issues of cardiovascular diseases, 2016, 2: 75-82. Russian (Эрлих А.Д., Барбараш О.Л., Кашталап В.В., Грацианский Н.А. Степень следования клиническим руководствам при остром коронарном синдроме без подъема ST: связь с исходами, предикторы «плохого» лечения (результаты регистра «Рекорд-3»). Комплексные проблемы сердечно-сосудистых заболеваний, 2016, 2: 75-82.
3. 2016 European Guidelines on cardiovascular disease prevention in clinical practice The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) European Heart Journal, 2016, 37: 2315-2381. doi:10.1093/eurheartj/ehw106.
4. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AMJr, Ridker PM, Grundy SM, Kastelein JJ. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol, 2014, 64: 485-494.
5. Catapano AL, Graham I, De Backer G. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS): Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J, 2016, Aug 27. pii: ehw272. DOI 10.1093/eurheartj/ehw272.
6. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason M.J., Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multi-centre randomised placebocontrolled trial. Lancet, 2004, 364: 685-696.
7. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37: 267-315. doi: 10.1093/eurheartj/ehv320.
8. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004, 350: 1495-1504.
9. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med, 2015, 372: 2387-2397.
10. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Filippatos G, Hasdai D, Hobbs R, Hoes A, Kearney P, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vardas P, Widimsky P, Windecker S, Funck-Brentano C, Berkenboom G, De Graaf J, Descamps O, Gotcheva N, Griffith K, Guida GF, Gulec S, Henkin Y, Huber K, Kesaniemi YA, Lekakis J, Manolis AJ, Marques-Vidal, Masana L, McMurray J, Mendes M, Pagava Z, Pedersen T, Prescott E, Rato Q, Rosano G, Sans S, Stalenhoef A, Tokgozoglu L, Viigimaa M, Wittekoek ME, Zamorano JL. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J, 2011, 32: 1769-1818.
11. Schiele F, Farnier M, Krempf M, Bruckert E, FerriПres J on behalf of the French Group. A consensus statement on lipid management after acute coronary syndrome. European Heart Journal. Acute Cardiovascular Care, 2016: 1-12.
12. Ferrieres J, Rouyer MV, Lautsch D, et al. Improvement in achievement of lipid targets in France: Comparison of data from coronary patients in the DYSIS and DYSIS II studies. Int J Cardiol, 2016, 222: 793-794.
13. Maddox TM, Borden WB, Tang F. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. J Am Coll Cardiol, 2014, 64: 2183-192.
14. Rosenson RS, Kent ST, Brown TM. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. J Am Coll Cardiol. 2015, 65: 270–277.
15. Arnold SV, Kosiborod M, Tang F, Zhao Z, Maddox
16. TM, McCollam PL, Birt J, Spertus JA. Patterns of statin initiation, intensification, and maximization among patients hos-pitalized with an acute myocardial infarction. Circulation, 2014, 129(12): 1303-9. doi: 10.1161/CIRCULATIONAHA.113.003589. Epub 2014 Feb 4.
17. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Effcacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010, 376: 1670-1681.
18. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA, 1999, 282: 2340-2346.
19. Cho KH, Jeong MH, Ahn Y, Kim YJ, Chae SC, Hong TJ, Seong IW, Chae JK, Kim CJ, Cho MC, Seung KB, Park SJ, Korea Acute Myocardial Infarction Registry Investigators. Low-density lipoprotein cholesterol level in patients with acute myocardial infarction having percutaneous coronary intervention (the cholesterol paradox). Am J Cardiol, 2010, 106: 1061-1068.
20. Oganov RG, Kukharchuk VV, Arutyunov GP, Galyavich AS, Gurevich VS, Duplyakov DV, Karpov YuA, Kobalava ZhD, Konstantinov VO, Martsevich SYu, Panov AV, Sergienko IV, Skibitskyi VV, Smolenskaya OG, Susekov AV, Tyurin VP, Shalaev SV, Maneshina OA, Brigida OV (on behalf of the DYSIS Study Group)]. Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study). Cardiovascular Therapy and Prevention, 2012, 11(4): 70-78. [in Russian]. Оганов Р.Г., Кухарчук В.В., Арутюнов Г.П., Галявич А.С., Гуревич В.С., Дупляков Д.В., Карпов Ю.А., Кобалава Ж.Д., Константинов В.О., Марцевич С.Ю., Панов А.В., Сергиенко И.В., Скибицкий В.В., Смоленская О.Г., Сусеков А.В., Тюрин В.П., Шалаев С.В., Манешина О.А., Бригида О.В. (от имени исследователей DYSIS*). Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика, 2012, 11(4): 70-78.
21. Reiner Z, De Backer G, Fras Z, Kotseva K, Tokgozoglu L, Wood D, De Bacquer D, On behalf of the EUROASPIRE Investigators. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries e Findings from the EUROASPIRE IV survey. Atherosclerosis, 2016, 246: 243-250.
22. Pogosova NV, Oganov RG, Boytsov SA, Ausheva AK, Sokolova OJ, Kursakov AA, Pozdnyakov YM, Salbieva AO, Lelchuk IN, TA, Gusarova TA, Gomyranova NV, Skazin NA, Yeliseeva NA, Akhmedova EB, Bedeynikova KK, Kovrigina MN. Monitoring the secondary prevention of ischemic heart disease in Europe and Russia: results of the Russian part of the International multicenter study EUROASPIRE IV. Kardiologiia. 2015, 55(12): 99-107 [in Russian]. Погосова Н.В., Оганов Р.Г., Бойцов С.А., Аушева А.К., Соколова О.Ю., Курсаков А.А., Поздняков Ю.М., Салбиева А.О., Лельчук И.Н., Гусарова Т.А., Гомыранова Н.В., Сказин Н.А., Елисеева Н.А., Ахмедова Э.Б., Бедейникова К.К., Ковригина М.Н. Мониторинг вторичной профилактики ишемической болезни сердца в России и Европе: результаты российской части международного многоцентрового исследования EUROASPIRE IV. Кардиология, 2015, 55(12): 99-107.
23. Akincigil A, Bowblis JR, Levin C. Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction. J Gen Intern Med, 2008, 23: 115-121.
24. Lee JH, Bae MH, Yang DH, Park HS, Cho Y, Jeong MH, Kim YJ, Kim KS, Hur SH, Seong IW, Cho MC, Kim CJ, Chae SC, Korea acute myocardial infarction registry investigators. Contemporary trends of optimal evidencebased medical therapy at discharge for patients surviving acute myocardial infarction from the Korea acute myocardial infarction registry. Clin. Cardiol, 2015, 38(6): 350-356.
25. Reiner Z, Tedeschi-Reiner E. Prevalence and types of persistent dyslipidemia in patients treated with statins. Croat. Med. J., 2013, 54: 339-345.
26. Reiner Z, Sonicki Z, Tedeschi-Reiner E. Physicians’ perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis, 2010, 213: 598-603.
27. Sonicki Z, Reiner Z, Tedeschi-Reiner E. Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey. Prev. Med., 2010, 51: 494-496.
28. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. J. Clin. Lipidol., 2012, 6 (3): 208-215.
29. Kjekshus J, Apetrei E, Barrios V, BЪhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, JЗnosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med, 2007, 357: 2248-2261.
30. Wei MY, Ito MK, Cohen JD. Predictors of statinadherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol, 2013, 7: 472-483.
31. Ganga HV, Slim HB, Thompson PD. Asystematic review of statin-induced muscle problems in clinical trials. Am Heart J, 2014, 168: 6-15.
32. Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Alirocumab for the treatment of hypercholesterolaemia. Expert Opin Biol Ther, 2017 Mar 9. doi:10.1080/14712598.2017.1305354.
33. du Souich P, Roederer G, Dufour R. Myotoxicity of statins: Mechanism of action. Pharmacol Ther, 2017 Feb 14. pii: S0163-7258(17)30043-8. doi:10.1016/j.pharmthera.2017.02.029.
34. Koslik HJ, Meskimen AH, Golomb BA. Physicians’ Experiences as Patients with Statin Side Effects: A Case Series. Drug Saf Case Rep, 2017 Dec, 4(1): 3. doi:10.1007/s40800-017-0045-0.
35. Tobert JA, Newman CB. Statin tolerability: In defence of placebo-controlled trials. European Journal of Preventive Cardiology, 2016, 23(8): 891-896.
36. Zhang H, Plutzky J, Skentzos S. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med, 2013, 158: 526-34.
37. Grundy S, Brown WV. From the editor: An interview with Dr. Scott Grundy. J Clin Lipidol, 2014, 8: 1-8.
38. Hauser W, Hansen E, Enck P. Nocebo phenomena in medicine: Their relevance in everyday clinical practice. Dtsch Arztebl Int, 2012, 109: 459-465.
39. Mampuya WM, Frid D, Rocco M. Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience. Am Heart J, 2013, 166: 597-603.
40. Ridker PM, Mora S, Rose L, on Behalf of the JUPITER Trial Study Group. Per cent reduction in LDL cholesterol following high-intensity statin therapy: potential implications-for guide lines an for the prescription of emerging lipid-lowering agents. European Heart Journal, 2016. doi: 10.1093/eurheartj/ehw046.
41. Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfeld MJ, Devlin JJ, Nordio F, Hyde CL, Cannon CP, Sacks FM, Poulter NR, Sever PS, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: ananalysis of primary and secondary prevention trials. Lancet, 2015. doi 10.1016/S0140–6736(14)61730-x.
42. Perrone V, Sangiorgi D, Buda S, Degli Esposti L. Residual cardiovascular risk in patients who received lipid-lowering treatment in a real-life setting: retrospective study. Clinicoecon Outcomes Res, 2016 Oct 25, 8: 649-655.
43. Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac
44. L, Minini P, Eckel RH, Cannon CP. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of
45. ODYSSEY Trials Comparing Alirocumab With Control. Circulation, 2016 Dec 13, 134(24): 1931-1943. Epub 2016 Oct 24.
46. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc
47. G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy
48. M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari
49. U, Kastelein JJ, ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med, 2015 Apr 16, 372(16): 1489-99. doi:10.1056/NEJMoa1501031. Epub 2015 Mar 15.
50. Colhoun HM, Ginsberg HN, Robinson JG, Leiter LA, MЯller-Wieland D, Henry RR, Cariou B, Baccara-Dinet MT, Pordy
51. R, Merlet L, Eckel RH. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. Eur Heart J, 2016, 37(39): 2981-2989. Epub 2016 Jul 26.
52. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393). Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta393. https: //www.nice.org.uk/guidance/ta393.
Рецензия
Для цитирования:
Барбараш О.Л., Кашталап В.В. КОНТРОЛЬ ЛИПИДОВ У ПАЦИЕНТОВ ПОСЛЕ ПЕРЕНЕСЕННОГО ИНФАРКТА МИОКАРДА — ЭФФЕКТИВНЫЙ ИНСТРУМЕНТ УПРАВЛЕНИЯ СЕРДЕЧНО-СОСУДИСТЫМ РИСКОМ. Атеротромбоз. 2017;(1):94-104. https://doi.org/10.21518/2307-1109-2017-1-94-104
For citation:
Barbarash O.L., Kashtalap V.V. LIPID CONTROL IN PATIENTS AFTER MYOCARDIAL INFARCTION - AN EFFECTIVE TOOL FOR MANAGING CARDIOVASCULAR RISKS. Aterotromboz = Atherothrombosis. 2017;(1):94-104. (In Russ.) https://doi.org/10.21518/2307-1109-2017-1-94-104
Просмотров:
1387
Контент доступен под лицензией Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Послать статью по эл. почте 